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ABSTRACT 
 
Symptoms of Parkinson Disease (PD), the second most common  
neurodegenerative disease, emerge due to degeneration of dopaminergic neurons. 
Approximately 10% of PD is familial with a number of genes that have been 
recognized to play a role. In 2012, a genome wide study revealed a role for the foxO 
transcription factor in PD. To more fully understand human diseases, model 
organisms such as Drosophila melanogaster are widely used. In the present study, I 
have attempted to model Parkinson Disease in Drosophila by foxO modulation using 
RNAi transgenes. To achieve this goal, I conducted longevity assays and locomotion 
measurements along with supportive experiments that target expression in the 
developing eye. Results suggest that under certain conditions, slight elevation of foxO 
by down-regulation of one of foxO’s inhibitors, the kinase minibrain (mnb), can 
model PD in flies. Results are presented here showing that expression of mnb-RNAi 
(and predicted subsequent slight elevation of foxO) in dopaminergic neurons results in 
significant loss of climbing ability: the defining feature of PD models in fruit flies. 
Other results suggest that slight decrease of  foxO by foxO-RNAi decreases life span 
significantly when expressed under the control of TH-Gal4( Tyrosine Hydroxylase-
Gal4) . In addition, results show that GFP-RNAi expression under the control of TH-
Gal4 reduces life span significantly.  
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INTRODUCTION 
 
Parkinson Disease 
 
Parkinson Disease (PD), after Alzheimer Disease, is the second most common  
neurodegenerative health concern and the most prevalent neurodegenerative 
movement disorder (Schiesling et al., 2008). Pathologically, PD for the most part, is 
characterized by the loss of dopaminergic neurons (DA neurons) in the ventral 
mesencephalic substantia nigra pars compacta. Another hallmark seen in most cases 
of PD, is the formation of Lewy bodies (aggregation of proteins including α-
synuclein) in the neurons of ventral midbrain and some other regions such as 
prefrontal cortex. For a long time after its initial description by James Parkinson in 
1817, PD was considered a non-genetic condition. It is only for a few decades that we 
have begun to understand that inherited forms (autosomal-dominant and autosomal-
recessive) of the disease account for 5 to 15% of all PD cases. What causes sporadic 
PD is not completely clear and it might vary in different forms of the disease, but it is 
thought that emergence of the disease is most likely the result of interplay between 
genetic susceptibility factors and the environmental agents which act on the 
background of an ageing brain (de Lau and Breteler, 2006). Regardless, it has been 
found that compared to the general population, life span in PD patients is reduced.  
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Sporadic or idiopathic PD as a consequence of loss of DA neurons which are 
vulnerable to degeneration (Levine et al., 1994) and subsequent impairment of 
innervation of the putamen affects motor abilities and cognitive function. The 
associated impairments often include resting tremor, rigidity, bradykinesia and 
postural instability; PD affects more than 1% of the population by the age of 65 years 
and approximately 4 to 5% by the age of 85 years and it seems to be increasing in 
occurrence with the increased life expectancy (Trinh et al., 2014). Affected cognitive 
functions, particularly in advanced stages of PD, include dementia, depression, 
fatigue, mood disorders, sleep problems, olfactory changes and anxiety. Despite the 
reality that the definite cause of PD is not known, a number of studies attribute the 
cumulative effects of oxidative stress, inflammation, mitochondrial dysfunction, and 
impaired proteasomal degradation to cause sporadic PD.  
Depending upon the circumstances, the occurrence of sporadic PD and familial 
PD may vary. The discovery of genes implicated in heritable forms of PD has 
provided new insights into the molecular events leading to neurodegeneration, which, 
in turn, can be applicable to both categories of the disease. Mutations in the genes 
PARK1, PARK3, PARK4, PARK5, PARK8, PARK11,VPS35 and EIF4G1 are 
associated with autosomal dominant forms of PD and mutations in PARK2, PARK6, 
PARK7 and PARK9 are associated with autosomal recessively inherited PD. The latter 
is characterized by selective dopaminergic neural cell death and the absence of the 
Lewy body (Shimura et al, 2000). In addition, mutations of polyglutamine disease 
genes are shown to contribute to sporadic PD symptoms.   
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These genes include: HTT, ATXN1, ATXN2, ATXN3, CACNA1A and TBP (Yamashita 
et al., 2014). It is worth mentioning that most of these genes normally regulate the 
various enzymes involved in protein degradation by the proteasomal pathway. 
To name some functions associated with familial PD genes, it can be said that  
the α-synuclein gene encodes a soluble 140 amino acid protein that  is the main 
component of lewy bodies (Olanow and  Brundin, 2013). The α-synuclein gene may 
act to integrate presynaptic signalling and membrane trafficking, and defects in this 
gene have been implicated in the pathogenesis of PD. The LRRK 2 gene encodes a 
protein that associates with the mitochondrial outer membrane, and mutations within 
this gene lead to an autosomal dominant form of the disease (Bonifati, 2006). The 
PARK2 gene encodes a multiprotein E3 ubiquitin ligase complex that mediates the 
targeting of substrate proteins for proteasomal degradation, and its mutations has been 
found to be linked with the autosomal recessive form of PD (Shimura et al., 2000). 
The PARK 7 gene encodes a redox-sensitive chaperone that functions as a sensor for 
oxidative stress, which apparently protects neurons against oxidative stress and cell 
death. In the treatment of this progressive disease, a number of approaches and 
therapeutic steps are among the most common and reveal the ongoing research trends 
in the area of PD treatment. These include 1) Drugs that mostly are intended to re-
establish striatal dopamine levels in the patients; 2) Viral-vector mediated ‗in vivo’ 
gene therapy; 3) Transplantation of embryonic stem cell, fetal midbrain dopaminergic 
neuron and encapsulated cells, and 4) Continuous infusion of trophic factors. 
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However, as there is no absolute curative treatment currently existing for PD, the 
importance of investigation into the cellular /molecular basis of PD is evident. 
 
Model Organisms 
 
Model organisms can be defined as ‗in vivo’ media for experiments that in  
humans would be unfeasible or unethical. Research on model organisms can focus on 
a wide variety of experimental techniques and goals from different areas of biology—
from ecology, behaviour, and biomechanics, to the functional scale of tissues, 
organelles, and proteins (Meunier et al., 2012). There are many model organisms 
among viruses, prokaryotes and eukaryotes, unicellular and multicellular organisms; 
in plant and animal phyla each probably apt for certain studies (Bernards and 
Hariharan, 2001). Generally, when researchers look for an organism to employ in their 
studies, they look for several features, most notably size, generation time, 
accessibility, ease of manipulation, genetic wealth of knowledge, conservation of 
mechanisms, and potential economic benefits. In the same spirit, it can be proposed 
that multiple model systems can be employed in cross-genomic analysis of human 
disease genes to address different health issues. For instance, Drosophila 
melanogaster and Caenorhabditis elegans are excellent models for examining the 
coordinated actions of genes that function as components of a signal-transduction 
pathway.  
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Drosophila melanogaster  
 
Extensive use of Drosophila melanogaster as a model system to answer  
questions in human genetics arises from the fact that Drosophila is indeed a well-
studied organism, and in fact many landmark discoveries in the field of Biology have 
been made possible by this tiny insect, some of which resulted in the awarding of the 
Nobel Prize. To name some of these discoveries, I should mention great findings by 
T.H. Morgan on sex-linked traits and independent segregation of traits on separate 
chromosomes and linkage of traits on the same chromosome in 1910 and 1911, X-ray 
induced mutagenesis by H.J. Muller in 1930, the concept that developmental genes act 
in spatially localized manner by E. Lewis in 1978, and the use of a saturation screen 
for developmental patterning genes by E. Wieschaus, G. Jürgens, C. Nüsslein-
Volhard, in 1980 (Ahmed et al., 2014). Aspects that facilitate extensive studies on 
Drosophila include but are not limited to having conserved developmental processes 
(typical examples: HOX Genes and neural induction) and shared mechanisms for 
human developmental disorders.  
Merits of Drosophila melanogaster include the following: 1) it has well-  
established genetics, and the molecular tools for precise genetic manipulations are 
available; 2) Drosophila has 14400 genes on their four chromosomes of which are 
61% similar to human genes, the fact that makes it a better model organism than other 
systems such as nematode and yeast. 
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 3) it has been found that 77% of human disease genes have fly counterparts (Reiter et 
al., 2001) and there are matches to diseases in categories as diverse as cancer, cardiac 
diseases, neurological diseases, immune dysfunction, metabolic and developmental 
disorders. 4) Drosophila has a short generation time (~10 days) and a high number of 
progeny (around 100 flies); and 5) it has a completely sequenced. 
 
Drosophila eye development 
 
The adult Drosophila eye is made of 750 to 800 multicellular units called  
ommatidia (Perry, 1968). Each ommatidium is a cluster of 20 cells that contain 8 
photoreceptors neurons, 8 pigment cells, and 4 lens secreting cone cells. 
Mechanoreceptory bristles are located in regular distances from ommatidia and are 
composed of four cells with one of them being a neuron. Thus, the developing eye is 
one neuron-rich tissue in which eye distortion caused by cell death or developmental 
defects can be detected. 
 
Gal4/UAS System 
 
Drosophila researchers owe much of their knowledge of biological events to  
ongoing progression in analytic and detection tools and techniques. 
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 As our tool-box expands, we are more and more able to gain closer, more accurate 
insight into what biological processes are like. One very practical example of facility 
development is the invention of the Gal4/UAS system for targeted gene expression in 
Drosophila. This system enables us to investigate the function of genes implicated in a 
wide variety of biological processes. Gal4 encodes a protein of 881 amino acids, 
identified in the yeast Saccharomyces cerevisiae as a regulator of genes (e.g., Gal10 
and Gal1) induced by galactose (Laughon et al., 1984). Gal4 regulates the 
transcription of Gal10 and Gal1 genes by directly binding to four related 17 basepair 
(bp) sites located between these loci (Giniger et al., 1985). The Upstream Activating 
Sequences (UAS) to which Gal4 binds is CGG-N11-CCG, where N can be any base 
(Campbell et al., 2008). UAS is essential for the transcriptional activation of these 
Gal4-regulated genes and has the same function as an enhancer element found in 
multicellular eukaryotes.  
 Expression of Gal4 in Drosophila initially appeared to have no adverse effect  
on phenotypes and  an important article describing the development of the Gal4/UAS 
system for targeted gene expression in Drosophila was published (Brand and 
Perrimon, 1993). However, later on some researchers reported that expression of Gal4 
in the dopaminergic neurons can significantly decrease life span (Haywood et al., 
2002) and that directed expression of this regulator in the eye region can lead to cell 
death (Kramer and Staveley, 2003). Although some care must be exercised in 
experimental design and interpretation of the phenotype, the Gal4/UAS system has 
become invaluable in Drosophila research. 
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In the Gal4/UAS system, expression of the gene of interest is controlled by the  
UAS element and as GAL4 is still absent in this line, the responder line remains silent. 
To activate their transcription, responder lines are crossed to flies expressing Gal4 in a 
particular spatiotemporal pattern. The resulting progeny then express the gene of 
interest in a transcriptional pattern that reflects the Gal4 pattern of the corresponding 
driver (Duffy, 2002). It has been found that Gal4 activity in Drosophila is dependent 
upon temperature and it is minimal at 16°C and reaches its maximum at 29°C 
providing a wide range of target gene expression levels and albeit affecting growth in 
turn. As a general rule, it is crucial to ensure that the biological process of  
study is not affected by the presence of either the Gal4 protein or the responder. Plus 
in selecting between maternal or paternal use of driver and responder lines, one might 
want to keep in mind the drastic developmental difference existing between 
Drosophila egg and sperm, potential effect of large bulk of maternal factors deposited 
inside the egg only (Giordano et al., 2002). The Gal4/UAS system can be employed to 
study both gain-of-function and loss of function phenotypes (Figure 1).  
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Figure 1. Gal4/UAS system. Tissue specific targeted gene expression is made possible 
by Gal4/UAS system: transcription factor Gal4 binds its cis-acting element Upstream 
Activating Sequesnce (UAS) and promotes the expression of target gene or sequence 
of interest. 
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Transgenic RNAi in Drosophila 
  
The Gal4/UAS system is used to direct the expression of a hairpin double- 
stranded RNA which will be processed by dicer enzymes into siRNAs to direct 
sequence-specific degradation of the target mRNA. These constructs are made by 
cloning short gene fragments (300-400 bp) as inverted repeats in the antisense-sense 
orientation into a modified pUAST vector with 10 copies of UAS sites. To generate 
300-400 bp gene fragments, primers are designed to PCR amplify DNA from any 
predicted protein-coding gene in the Drosophila genome sequence (Fire et al., 1998). 
RNAi libraries are constructed as genetic screens in model organisms and have 
provided remarkable insights into numerous aspects of development, physiology and 
pathology. With the availability of complete genome sequences and the introduction 
of RNA-mediated gene interference (RNAi), systematic reverse genetic screens have 
become possible. This powerful tool can be applied in a tissue-specific manner able to 
the conditional inactivation of gene function in specific tissues of the intact organism 
(Dietzl et al., 2007). To date, approximately 22,270 transgenic lines are generated, 
covering 88% of the predicted protein-coding genes in the Drosophila genome.  
Molecular and phenotypic assays indicate that most of these transgenes are functional. 
The transgenic RNAi libraries open the prospect of systematically analyzing gene 
functions in any tissue and at any stage of the Drosophila lifespan.  
 
 
11 
 
fork-head box O (foxO) Transcription Factor 
 
forkhead genes encode a subgroup of the helix-turn-helix class of proteins  
that act as transcription factors or regulators. A defining feature of the foxO protein is 
the forkhead box, a sequence of 80 to 100 amino acids forming a motif (called 
Winged Helix motif due to the butterfly-like appearance of the loops) that bind to 
DNA (Tuteja et al., 2007), and as their function suggests, they contain both Nuclear 
Localization sequence (NLS) and Nuclear Export Signal (NES) which are the main 
sites of foxO modulation. Originally, foxO genes were given very different names 
(such as HFH, FREAC, and fkh), but in the year 2000 a unified nomenclature was 
used that grouped the fox genes into 19 subclasses (foxA-foxS) based on sequence 
conservation. Protein multiple alignment results suggest that they present high level of 
conservation within different species. There are 4 mammalian foxO members 
foxO1/FKHR/foxO1a, foxO3/FKHRL1/foxO3a, foxO4/AFX and FoxO6 (Calnan and 
Brunet, 2008), one homologue in C. elegans (DAF-16) (Perens and Shaham, 2005) 
and one homologue in Drosophila melanogaster (dfoxO) (Kramer et al., 2003). foxO 
proteins are conserved in pathways that play a role in coordination of cellular 
responses to changes in inner or outside environment and seem to do so by 
transcriptional regulation of many target genes and interactions with a vast range of 
transcriptional regulators that affect cell functions such as cell cycle, apoptosis and 
metabolism.  
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foxO modifiers  
 
The foxO protein can be modified through different post transcriptional  
modifications including acetylation, ubiquitination and phosphorylation. Akt is a 
kinase that can phosphorylate foxO both in the cytoplasm and the nucleus on the three 
sites of T32, S253 and S315 both ‗in vitro’ and ‗in vivo’ (all mammalian foxO 
proteins contain three Akt phosphorylation sites except for foxO6), and this 
phosphorylation leads to nuclear exclusion of foxO3 (Brunet et al., 1999). Akt-
mediated nuclear exclusion of foxO is facilitated by 14-3-3 proteins (Morrison, 2009), 
a family of conserved modulator proteins that regulate different signaling pathways in 
the cell by binding to specific Ser/Thr-phosphorylated motifs on target proteins and 
affect their function by means of altering the enzymatic activity of the target protein, 
protein stability or cellular localization. The foxO protein is one main component of 
the insulin signalling pathway and it plays a role in nutrient constraint conditions; it is 
involved in stress resistance response and inhibits growth, through the action of target 
genes such as d4E-BP (Jünger et al., 2003). It has been shown that in C. elegans, an 
absence of Akt signalling activates DAF-16 (the foxO homologue) and causes dauer 
formation (Kops et al., 2002) promoting cell entering into quiescence and/or 
protecting these cells against oxidative stress.  
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It has been found that foxO proteins can be phosphorylated on multiple sites  
besides Akt sites such as at Ser329, which has been found to utilize another kinase, 
dyrk1a (dual-specificity tyrosine-phosphorylation regulated kinase 1a (Woods et al., 
2001)). dryk1a is located within the Down Syndrome Critical Region of human 
chromosome 21 and the minibrain gene, the Drosophila homologue of human dyrk1a, 
is located on first chromosome (chromosome X) of Drosophila. There are several 
isoforms of minibrain protein, a potentially nuclear protein, with the one closest to 
human homologue being mnb isoform E. mnb genes encode kinases being able to 
phosphorylate serine/threonine residues on other proteins as well as auto-
phosphorylation of tyrosine residues on the mnb protein itself (Hong et al., 2012). The 
minibrain protein isoform E consists of 908 amino acids and contains a distinct 
amino-terminal domain, a kinase core domain, and a variable C-terminal. Studies 
done on mice reveal that increased dyrk1a expression leads to Down Syndrome-like 
phenotypes (Arron et al., 2006) and mnb has been shown to play role in 
postembryonic neurogenesis. Mutations within the mnb gene cause a reduced optic 
lobe in adult flies and abnormal spacing of neuroblasts in the larval brain (Tejedor et 
al., 1995). mnb has been shown to share 85% amino acid similarity within the 
catalytic site which consists of a conserved motif of YQY (dyrk1a) and YHY (mnb) 
(Kentrup et al., 1996). Moreover, mnb contains a nuclear translocation signal a 
tyrosine-rich hydrophilic region, responsible for nuclear localization, a 13- histidine 
repeat region possibly for metal binding and a motif of 17 clustered serine/threonine 
residues that may be putative phosphorylation sites.  
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One target of dyrk1a/mnb is the foxO1 transcription factor, and  
phosphorylation of foxO by mnb  on serine 329 sequesters it from the nucleus (Figure 
2) . In our lab (Inpken and Staveley, unpublished), it has been observed that when 
mnb and foxO were both expressed in the eye, mnb appears to partially rescue the 
foxO phenotype. Therefore, mnb seems to act as an inhibitor of foxO and it exerts its 
effects on foxO protein by post translationally phosphorylating foxO. Other than 
phosphorylation which in most cases leads to foxO nucleus sequestration and thus 
inactivation, there are other mechanisms that each might act independently or with 
cross talk to the Akt pathway, namely reversible acetylation, methylation and 
ubiquitination, some of the effect of which is quite controversial (Daitoku, et al., 
2004). For example, the exact effect of acetylation on foxO activity according to some 
results is increased foxO activity while other results suggest quite the reverse (Huang 
and Tindall, 2011). As for foxO regulation by ubiquitination, it is important that if 
foxO protein has already been induced by phosphorylation (by Akt, Erk-1/2 and Ikk) 
or is it undergoing mono-ubiquitination or polyubiquitination which targets foxO for 
degradation. 
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Cell Nucleus 
 
 
 
 
 
Figure 2. Proposed relationship between mnb kinase and foxO. It is proposed that mnb 
kinase exerts its effects on foxO transcription factor by phosphorylation and inhibiting 
its nuclear translocation thus inhibiting its effect on target genes. 
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Research Statement: 
 
Considering the importance of studies on degenerative diseases to increase the  
wealth of knowledge and since the recent publication on the implication of foxO1 in 
PD patients (Dumitriu et al., 2012), I decided to have a closer look at foxO modulation 
in terms of its potential in modeling PD. In study carried out by Dumitriu and 
colleagues in 2012, they produced and analyzed expression data from the prefrontal 
cortex Brodmann Area 9 (one of the brain regions that become affected in PD besides 
substantia nigra pars compacta). They found 507 out of the 39,122 analyzed 
expression probes different between PD and control samples. One of the genes with 
significantly increased expression in PD was the forkhead box O1 (FOXO1) 
transcription factor.  To investigate the role of foxO transcription factor in Drosophila 
models of PD, I employed an RNAi approach for its subtle nature of 
elevating/decreasing gene expression and Drosophila melanogaster for its 
convenience as a model organism. As the direct overexpression of foxO in 
dopaminergic neurons did not generate viable progeny (Staveley unpublished), I used 
mnb-RNAi to indirectly elevate foxO transcription factor levels in the nucleus and 
foxO-RNAi for the direct decrease of foxO.  
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I designed a set of experiments to obtain a better insight into the role of foxO  
in inducing cell degeneration and I hypothesized that elevation of foxO in 
dopaminergic neurons would provide a Drosophila model of PD in some aspects. 
Therefore, I employed locomotion assay and also carried out longevity assay and eye 
morphology experiments. With the literature reporting on the inhibitory effect of mnb 
on foxO and the implication of foxO in PD, my initial prediction was that expression 
of mnb-RNAi thus slightly elevating foxO activity in dopaminergic neurons using 
Tyrosine Hydroxylase-Gal4 (TH-Gal4) driven expression and/ or dopa-
decarboxylase-Gal4 (ddc-Gal4) will result in diminished climbing ability in flies 
while both experiment and control group of flies would exhibit a similar life span.  
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MATERIALS AND METHODS 
Drosophila Culture and Stocks 
Drosophila melanogaster stocks were kept at  room temperature and all the  
experiments were maintained in a 25 ºC incubator. All stocks and crosses were raised 
in a medium containing 65 g/L cornmeal, 50 ml/L fancy grade molasses, 10 g/L yeast, 
5.5 g/L agar and ~ 900 ml water and stocks solid media was changed for new fresh 
food every two to three weeks. Drosophila media was prepared by Dr. Staveley and 
treated with 2.5 ml/L propionic acid and 5 ml/L of 10% methylparaben in ethanol to 
prevent mold growth, and then 7 ml of media was poured into each vial and stored in 
refrigerator at 4 to 6ºC after cooling at room temperature and becoming solid.As 
shown in Table 1, a series of ten fly lines was utilized in the experiments. TH-Gal4 
along with the GMR-Gal4 (Freeman, 1996), UAS-lacZ (Brand and Perrimon, 1993), 
UAS- mnb-RNAi
 
 and  UAS-foxO-RNAi
 
 obtained from Bloomington Stock Center at 
Indiana University. ddc-Gal4 (Li et al., 2000) was kindly provided by Dr. Jay Hirsh 
(University of Virginia) and w
118
; GMR-Gal4/CyO;UAS-foxO/TM3 compound line 
was generated by Dr. Staveley. Directed expression of the transgenes in the eye region 
was accomplished by crossing responder lines and GMR-Gal4 females whereas 
directed expression of transgenes in DA neurons was achieved by crossing responders 
to TH-Gal4 and ddc-Gal4 females. All crosses were done as per standard methods and 
only male flies of each critical class were collected to avoid possible affected 
longevity in females.  
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Table 1. Genotype and related information of Drosophila stocks. 
Genotype and stock 
numbers 
Chromosome(s) affected  Comments  
TH-Gal4 (8848) 1,3 Expresses GAL4 in dopaminergic neurons 
Ddc-GAL4 2 Expresses GAL4 in dopaminergic neurons 
(Li et al., 1997) plus serotonergic neurons 
(Alic et al., 2012) 
GMR-Gal4 (b1104) 1, 2 Expresses GAL4 in the eye disc, provides 
strong expression in all cells behind the 
morphogenetic furrow (Freeman, 1996) 
UAS-lacZ 
4-2-1
 (b2128) 2 Expresses lacZ under UAS control 
(Brand and Perrimon, 1993) 
UAS-GFP-RNAi 
(b9330) 
1,3 Expresses a dsRNA of GFP under UAS 
control 
UAS-mnb-RNAi 
(b35222) 
1,3 Expresses dsRNA for RNAi of mnb under 
UAS control 
UAS-foxO-RNAi
 
(v106097)
 
2 Expresses dsRNA for RNAi of foxO under 
UAS control 
w118; GMR-Gal4 
/CyO;UAS-foxO/TM3 
 Two balancer chromosomes used. Expresses 
both Gal4 and foxO in the eye 
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Scanning Electron Microscopy of the Drosophila eye  
 
Approximately ten males from each cross were collected and aged upon  
standard media at 25 º C for three to five days to allow for phenotypic stabilization 
before storing at -80º C. Frozen flies were examined under a dissecting microscope 
then mounted on aluminum studs and allowed to undergo desiccation for 
approximately 48 hours (gold-coating was not required). Samples were visualized by 
using an MLA 650F Scanning Electron Microscope chamber (Memorial University of 
Newfoundland CREAIT Facility) and 10 pictures (597 times magnification) per 
genotype were captured for further analysis. The area of the eye was measured based 
on the presence of Ommatidia. The area of a single ommatidium was determined by 
measuring the average area of a ―floret‖ of ommatidia consisting of a central unit 
surrounded by six others then dividing by 7. Counts and measurements were 
conducted  using software ImageJ 1.42q (Abramoff et al., 2004) and the data were 
transferred to Graph Pad Prism 5 (Graphpad Software, San Diego California USA, 
www.graphpad.com) for drawing bar graphs and analysis to detect any significant 
difference between the numerical values. 
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 Longevity Assay 
 
To perform longevity assays, critical class genotype were collected under  
carbon dioxide every 24 hours until a minimum of approximately 200 critical class 
(males of desired genotype) flies were obtained. They were then transferred into 
upright standard plastic vials containing standard media and kept in numbers of no 
more than 20 to prevent overcrowding. As flies aged they are transferred to new food 
without anaesthesia and monitored for viability until all have perished (Staveley et al., 
1990). The longevity of the flies were recorded manually on ageing sheets and then 
transferred to Prism 5 software (Graphpad Software, San Diego California USA, 
www.graphpad.com) for analysis. Survival fractions were calculated using the product 
limit (Kaplan-Meier) method and the statistical test of Mantel-Cox was carried out to 
detect any significant difference between survival curves (longevity assay was done 
three times overall). 
Locomotor Activity Assay 
 
Locomotor activity of flies was assessed using a series of climbing  
experiments (Todd and Staveley, 2004) over the life of a cohort of flies. In this assay 
which was done three times overall, seventy or so males of critical class of each cross 
were collected within 24 hours post eclosion and placed into vials in groups of ten. 
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They were maintained on standard media and were assayed for climbing ability in 
intervals of seven days starting at day four or five after eclosion. A funnel was used to 
transfer flies to the apparatus and then sponges were put into both ends of the tube to 
prevent flies from escaping and allow gas exchange to occur.  Each time, flies from 
each tube were put in a climbing apparatus which is a 30 cm glass tube with a 
diameter of 1.5 cm divided into five 2 cm sections graduated from 1 to 5 (remaining 
20 cm of the tube acts as a buffer zone that limits the interference between flies during 
climbing).  Following the natural negative geotaxis response, flies walk up the tube 
after being tapped on a surface and their ability to climb was evaluated at 10 seconds 
10 trials per day per cohort. The section each fly climbed to was recorded and the 
numbers put in the ―Climbing index‖ formula: Climbing index = Σ (nm)/N where n is 
the number of flies, m is the section (1-5) and N is the total number of flies in that 
trial. The data then were transferred to Prism 5 (Graphpad Software, San Diego 
California USA, www.graphpad.com) for analysis. Essentially, the climbing 
experiment was terminated when either there was no or very few flies left alive or 
their climbing ability was so diminished that is near to complete loss. To compare 
climbing ability, climbing indices were subtracted from 5 to follow the inverting the 
y-axis of the graphs and it was determined via a non-linear regression curve fit within 
a 95% confidence interval (CI). Unpaired t-test was carried out to detect any 
significant differences between means of groups and the slopes of the curves with 
non-overlapping 95% CI were considered significantly different. 
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RESULTS 
 
 GFP-RNAi under the control of GMR-Gal4 does not alter development in D. 
melanogaster eyes raised at 25 ºC. 
The Glass Multiple Reporter gene (GMR)-Gal4 transgene (Freeman, 1996),  
causes high levels of expression in Drosophila eye imaginal discs. Flies heterozygous 
for GMR-Gal4 do not show an apparent abnormal phenotype at 25º C (Kramer and 
Staveley, 2003). Figure 3A and 3B display SEM images of D. melanogaster eyes with 
targeted expression of lacZ or GFP- RNAi at 25 º C. GFP-RNAi construct expresses 
dsRNA to target non-existent in fly GFP mRNA molecule. The rationale for applying 
such line is to determine if GFP-RNAi can act as control in RNAi experiments. The 
Rationale for using GMR-Gal4/UAS-lacZ as opposed to w1118 as a control line is to 
try to compensate the effect of Gal4 transcription factor in the experiment. As lacZ 
system is not operating in flies at all and exogenous expression of lacZ has not proved 
any adverse effect, it is now widely used in fly experiments as a reliable control in 
UAS-Gal4 system.  Results show that in both genotypes eye morphology appears 
normal and statistical analysis does not reveal any significant difference in their 
ommatidia and bristle numbers as well as their ommatidia area, counts and 
measurements are graphed in Figure 3C, 3D and 3E. 
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Figure 3. The expression of GFP-RNAi has no effect on D. melanogaster eyes at 
25º C. A and B scanning electron micrographs of D. melanogaster eyes with the 
directed expression of lacZ (A) and GFP-RNAi under the control of GMR-Gal4 (B). 
Genotypes are GMR-Gal4/UAS-lacZ (A) and GMR-Gal4/UAS-GFP-RNAi (B). GFP-
RNAi does not alter ommatidia number compared to GMR-Gal4/UAS-lacZ (C). GFP 
RNAi does not influence the number of ommatidia (D) plus ommatidia area is not 
altered by GFP-RNAi (E). (N=10 p-value<0.05 is considered significant). Error bars 
represent standard error of the mean and NS indicates Not significant. 
A B
C D 
E 
NS NS 
NS 
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GFP-RNAi under the control of GMR-Gal4 alters the consequences of foxO 
overexpression in D. melanogaster eyes raised at 25º C. 
 
The expression of foxO in the Drosophila eye, directed by GMR-Gal4,  
produces an abnormal rough eye phenotype characterized by reduced number of 
ommatidia, partial absence of bristles and distorted eye periphery (Kramer et al., 
2003). GFP-RNAi enhances the phenotype induced by GMR-Gal4/UAS-foxO. The 
GMR-Gal4/UAS-foxO phenotype becomes more severe when GFP-RNAi (construct 
used to target non-existent GFP mRNA in Drosophila) is used (Figure 4B). Although 
ommatidia area is not significantly altered and bristles are absent in both GMR-
Gal4,UAS-foxO/UAS-lacZ and GMR-Gal4,UAS-foxO/UAS-GFP-RNAi genotypes, 
biometric analysis revealed a significant reduction in  ommatidia number in GMR-
Gal4,UAS-foxO/UAS-GFP-RNAi compared to the control. Figure 4A and 4B display 
SEM images of D. melanogaster eye with GFP-RNAi and with expression of lacZ in 
25 º C and Figures 4C, 4D and 4E illustrate the related graph. 
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Figure 4. The expression of GFP-RNAi enhances the phenotype induced by 
GMR-Gal/UAS-foxO in D. melanogaster eye raised at 25 º C. Scanning electron 
micrographs of GMR-Gal4,UAS-foxO/UAS-lacZ (A) and GMR-Gal4,UAS-foxO/UAS-
GFP-RNAi(B).GFP-RNAi reduces ommatidia number (p-value=0.0007) (C) but does 
not alter ommatidia area (D) or bristle number (E). N-value is 10, error bars represent 
standard error of mean, NS indicates Not Significant and asterisk indicates significant 
difference. 
A 
C 
E 
D 
B 
NS 
NS 
* 
27 
 
 
GFP-RNAi expression under the control of ddc-Gal4 reduces life span but not 
climbing ability in D. melanogaster raised at 25º C.  
 
GFP-RNAi in dopaminergic neurons plus some other cells using ddc-Gal4 - 
driven causes a decrease in life span compared to ddc-Gal4/UAS-lacZ flies (Figure 
3A). Median survival of ddc-Gal4/UAS-lacZ flies is 47 days and 38 days for ddc-
Gal4/UAS GFP-RNAi flies. Flies present slightly but not significantly decreased 
median life span when GFP-RNAi is expressed under the control of ddc-Gal4 
transgene. Mantel-Cox test was carried out to detect significant differences between 
two genotypes and the N-value is approximately 200. Figure 5A illustrates the related 
survival curve and Figure 5B displays climbing curves of the two genotypes: ddc-
Gal4/UAS-lacZ and ddc-Gal4/UAS-GFP-RNAi. One of the hallmark phenotypes of 
the Drosophila PD models is the premature loss of climbing ability and climbing 
ability over time of 70 males of critical class of two genotypes were evaluated. 
Climbing was continued until minimum of five alive flies were left. Statistical tests 
suggest that no significant difference existed among the genotypes. Figure 5B shows 
the fitted non-linear regression curves in ddc-Gal4/UAS-lacZ and ddc-Gal4 /UAS-
GFP-RNAi genotypes. The 95% confidence interval of the slopes were evaluated and 
found to overlap indicating that any observed differences are likely due to chance. 
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Figure 5. The expression of GFP-RNAi directed by ddc-Gal4 reduces life span but 
not climbing ability in D. melanogaster raised at 25 º C. GFP-RNAi directed  by 
ddc-Gal4 in dopaminergic neurons slightly decreases life span compared to ddc-
Gal4/UAS-lacZ control, N-value is 200 (A) Climbing ability (on 70 flies initially) is 
not significantly altered by GFP-RNAi directed by ddc-Gal4 in dopaminergic neurons 
of D. melanogaster (B). 
A 
B 
ddc-Gal4/UAS-GFP-RNAi 
ddc-Gal4/UAS-lacZ 
ddc-Gal4/UAS-lacZ 
ddc-Gal4/UAS-GFP-RNAi 
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GFP-RNAi expression under the control of TH-Gal4 reduces life span but not 
climbing ability. 
 
The TH-Gal4 transgene is used to direct the expression of a targeted gene  
exclusively in dopaminergic neurons. Here, the TH-Gal4 transgene was combined 
with the UAS-GFP-RNAi responder to induce GFP-RNAi expression in dopaminergic 
neurons and TH-Gal4/UAS-lacZ was selected as the control. 200 males of each critical 
class genotype were selected and their life span was compared. Survival curves 
displayed in Figure 6A shows that there is a significant decrease in life span when 
GFP-RNAi is expressed in dopaminergic neurons with TH-Gal4 transgene. The 
climbing ability over time however, was not significantly different between the 
genotypes of TH-Gal4/UAS-lacZ and TH-Gal4/UAS-GFP-RNAi. Figure 6B illustrates 
the climbing curves for the two genotypes. 70 males of each genotype of TH-
Gal4/UAS-lacZ and TH-Gal4/UAS-GFP-RNAi were selected to perform locomotor 
assay and the assay was continued until a minimum of five flies were left alive. 
Statistical analysis results did not reveal any significant difference in the two 
genotypes. Non-linear regression curves were fitted with a 95% confidence interval, 
curve slopes where compared and seen to overlap thus indicating that any observed 
differences are due to chance rather than a certain pattern. 
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Figure 6. The expression of GFP-RNAi directed by TH-Gal4 reduces life span 
significantly but does not alter climbing ability in D. melanogaster raised at 25 º 
C. (A) 200 male flies of critical class for two genotypes of TH-Gal4/UAS-lacZ and 
TH-Gal4/UAS-GFP-RNAi were collected for longevity assay. TH-Gal4/UAS-lacZ flies 
show a median life span of 38 days whereas TH-Gal4/UAS-GFP-RNAi critical class 
show median life span of 60 days. GFP-RNAi shortens life span very significantly 
according to Mantel-Cox test results. (B) 70 flies of critical class were initially chosen 
for locomotion assay over time in two genotypes of TH-Gal4/UAS-lacZ and TH-
Gal4/UAS-GFP-RNAi. Non-linear regression fitted curves and statistical analysis 
show that there is no significant difference in their climbing abilities over time. Error 
bars represent standard error of mean and asterisk indicates significant difference. 
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Expression of foxO-RNAi directed by GMR-Gal4 in the eye does not alter eye 
development in D. melanogaster raised at 25º C.  
 
The foxO-RNAi expression directed by GMR/Gal4 does not significantly alter  
the eye phenotype. In both genotypes of GMR-Gal4,UAS-foxO/UAS-lacZ and GMR-
Gal4,UAS-foxO/UAS-foxO-RNAi, external area of the eye is smooth and the number 
of ommatidia is approximatley 700 and the number of bristles is approximately 500. 
Expression of  foxO-RNAi in the eye does not make any dramatic difference in the eye 
morphology or in the number of ommatidia. Figures 7A and 7B show scanning 
electron micrographs of the two genotypes and Figures 7C, 7D and 7E display the 
related graphs. 
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Figure 7: The expression of foxO-RNAi directed by GMR-Gal4 does not alter D. 
melanogaster eye developed at 25º C. foxO-RNAi expression does not alter eye 
morphology (A and B). Genotypes are GMR-Gal4/UAS-lacZ (A) and GMR-
Gal4/UAS-foxO-RNAi (B). foxO-RNAi expression does not make any significant 
change in the ommatidia number (C), bristle number (D) and ommatidia area (E). P- 
value less than 0.05 is considered significant. N-value is 10, error bars indicate 
standard errors of mean and NS means Not Significant. 
A B 
C D 
E 
NS NS 
NS 
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Expression of foxO-RNAi supresses the severe foxO overexpression-induced 
phenotype in D. melanogaster eyes raised at 25º C. 
 
Eye development defects caused by overexpression of foxO is significantly but  
not completely suppressed by foxO-RNAi. GMR-Gal4,UAS-foxO/UAS-lacZ flies have 
developmental defects when raised at 25ºC. This phenotype improves when foxO-
RNAi is expressed in the developing eye. Scanning Electron Micrographs for both 
GMR-Gal4,UAS-foxO/UAS-lacZ and GMR-Gal4,UAS-foxO/UAS-foxO-RNAi  are 
shown in Figure 8A and 8B. Driving foxO-RNAi in the D. melanogaster eye using 
GMR-Gal4/UAS-foxO increased the number of ommatidia as well as the number of 
bristles in 25ºC. Biometric analysis showed that foxO-RNAi increased the mean 
ommatidia number from 400 to 650 (Figure 8C) and the mean number of bristles from 
5 to 500 (Figure 8D). foxO-RNAi did not alter ommatidia area significantly (Figure 
8E). 
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Figure 8. The expression of foxO-RNAi by GMR-Gal4 supresses the GMR-
Gal4/UAS-foxO eye phenotype in D. melagaster raised at 25º C. A and B Scanning 
electron micrographs of GMR-Gal4,UAS-foxO/UAS-lacZ and GMR-Gal4,UAS-
foxO/UAS-foxO-RNAi. foxO-RNAi partially rescued the reduced number of ommatidia 
(C) and  foxO-RNAi completely rescued the diminished bristle number (P-value < 
0.0001 and n=10) but did not alter ommatidia area (E). Error bars represent standard 
error of the mean. P-values calculated via unpaired t-test, NS means not significant 
and asterisk indicates significant difference. 
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foxO-RNAi expression under the direction of ddc-Gal4 does not alter life span or 
climbing ability in D.melanogaster raised at 25º C. 
 
When foxO-RNAi was expressed under the control of ddc-Gal4 transgene, it  
did not alter life span (Figure 9A). 200 males of critical class were selected for 
longevity assay and the survival pattern illustrated by survival curves was compared. 
Likewise, climbing ability was not altered when foxO-RNAi was expressed in 
dopaminergic neurons directed by ddc-Gal4 shown in figure 9B. 70 male of each 
genotype were selected for testing locomotor ability over time and continued until 
minimum number of five flies were alive. Both genotypes of ddc-Gal4/UAS-lacZ and 
ddc-Gal4/UAS-foxO-RNAi showed a roughly the same pattern of losing their climbing 
ability over time. 
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Figure 9. The expression of foxO-RNAi under the control of ddc-Gal4 transgene 
does not alter life span or climbing ability in D. melanogaster raised at 25º C. 
Longevity assay was performed on genotypes of ddc-Gal4/UAS-lacZ and ddc-
Gal4/UAS-foxO-RNAi flies and the pairwise comparison does not reveal any 
significant difference between survival patterns. N value= 200 (A). 70 (initially) to 5 
(minimum) males of critical class were  analysed by a locomotion assay over time and 
non-linear regression curve was fitted to best demonstrate the climbing over time 
pattern of two genotypes of ddc-Gal4/UAS-lacZ and ddc-Gal4/UAS-foxO-RNAi; in 
95% CI slopes overlap indicating any difference caused likely by chance (B). 
A 
B 
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The expression of foxO-RNAi directed by TH-Gal4 reduces life span but does not alter 
climbing ability in D. melanogaster raised at 25º C.  
 
200 males of critical class were selected from each genotype of TH-Gal4/UAS-  
lacZ and TH-Gal4/UAS-foxO-RNAi and a longevity assay was performed. foxO-RNAi 
expressed in dopaminergic neurons under the control of TH-Gal4 made a slight 
alteration in climbing ability over time and reduced life span. The survival curves 
(Figure 10A, P-value <0.001) decrease in life span when foxO-RNAi is induced in 
dopaminergic neurons under the control of TH-Gal 4 transgene. The median life span 
for TH-Gal4/UAS-lacZ  flies was 58 day whereas the median life span for the TH-
Gal4/UAS-foxO-RNAi flies was 38 days. Survival curves shown in figure 10A suggest 
that TH-Gal4/UAS-foxO-RNAi flies lived to a maximum of 60 days whereas TH-
Gal4/UAS-lacZ flies live to a maximum of 80 days. Figure 10B shows the fitted 
curves of climbing ability over time for two genotypes of TH-Gal4/UAS-lacZ and TH-
Gal4/UAS-foxO-RNAi. Pair-wise comparison of climbing ability over time for the two 
genotypes shows that the pattern of their climbing ability is different at days 26 and 
40. Climbing ability assay was performed with initially 70 males of critical class until 
a minimum of 5 flies were left alive. 
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Figure 10. foxO-RNAi expression directed by TH-Gal4 reduces life span 
significantly but not climbing ability in D. melanogaster raised at 25º C.  foxO-
RNAi induced in dopaminergic neurons under the control of  TH-Gal4 transgene 
shortens life span significantly as supported by Mantel-Cox test results, N-value=200 
(A). Comparison of climbing ability over time for the two genotypes shows that the 
pattern of their climbing ability is different at days 26 and 40. N-value is 70 (initially) 
to 5 (minimum) and genotypes are TH-Gal4/UAS-lacZ and TH-Gal4/UAS-foxO-RNAi 
(B) Error bars represent standard error of mean and asterisk indicates significant 
difference. 
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Expression of mnb-RNAi under the control of GMR-Gal4 does not alter eye 
development in D. melanogaster raised at 25º C. 
 
The mnb-RNAi transgene under the control of GMR-Gal4 did not make any  
significant difference in the number of ommatidia. mnb-RNAi in the eye also did not 
change ommatidia area and bristle numbers dramatically. The number of ommatidia in 
both genotypes of GMR-Gal4/UAS-lacZ and GMR-Gal4/UAS-mnb-RNAi was 
approximately 700 and the number of ommatidia is approximately 500 in GMR-
Gal4/UAS-lacZ and 480 in GMR-Gal4/UAS-mnb-RNAi. Figures 11A and 11B show 
scanning electron micrographs of GMR-Gal4/UAS-lacZ and GMR-Gal4/UAS-mnb-
RNAi flies respectively and Figure 9C-9E illustrate the related graphs. The number of 
ommatidia in both genotypes was approximately 700 and bristle number is 
approximately 500 plus the area of one ommatidium in both genotypes is close to 170 
µm
2.
 An unpaired t-test was carried out to detect any significant difference between 
the numerical values of the genotypes where P-value less than 0.05 is considered 
significant. Statistical analysis did not reveal any significant difference in the two 
counts and measurements between two genotypes of GMR-Gal4/UAS-lacZ and GMR-
Gal4/UAS-mnb-RNAi. So, eye development was not altered when mnb-RNAi is 
expressed under the control of GMR-Gal4.
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Figure 11. The expression of mnb-RNAi under the control of GMR-Gal4 does not 
alter eye development in  D. melanogaster raised at 25 º C. mnb-RNAi in the eye 
does not make any change in eye morphology (A and B). Genotypes are GMR-
Gal4/UAS-lacZ (A) and GMR-Gal4UAS-/mnb-RNAi (B) Eye biometric analysis does 
not show any significant difference in ommatidia number (C) and in the number of 
bristles (D) or in the ommatidia area (E) (N=10 and NS indicates Not Significant).  
A B 
C D 
E 
NS NS 
NS 
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The expression of mnb-RNAi directed by GMR-Gal4 does not significantly alter the 
GMR-Gal4/UAS-foxO phenotypes in D. melanogaster raised at 25º C. 
 
 The mnb-RNAi in the GMR-Gal4/UAS-foxO eye did not supress the foxO  
induced phenotype. Number of ommatidia, bristles and ommatidia area were not 
significantly altered. Figures 12 A and 12B show scanning electron micrographs of 
GMR-Gal4,UAS-foxO/UAS-lacZ (A) and GMR-Gal4,UAS-foxO/UAS-mnb-RNAi (B). 
There was not a significant reduction or increase in the number of ommatidia and 
bristle as well as the ommatidia area. Figures 12C-12E display the related graphs. 
Medium ommatidia number in GMR-Gal4,UAS-foxO/UAS-lacZ was 390 and it was 
380 in GMR-Gal4,UAS-foxO/UAS-mnb-RNAi. The ommatidia area was close to 180 
µm
2
 in GMR-Gal4,UAS-foxO/UAS-lacZ and 170 µm
2
 in GMR-Gal4,UAS-foxO/UAS-
mnb-RNAi. Unpaired t-test was carried out to detect any significant differences in 
numerical values where P-value less than 0.05 is considered significant. 
 
 
 
 
 
42 
 
   
 
 
 
 
 
 
 
 
Figure 12. The expression of mnb-RNAi in the GMR-Gal4/UAS-foxO eye did not 
significantly alter the GMR-Gal4/UAS-foxO phenotype in D. melanogaster raised 
at 25 ºC. Scanning electron micrographs of GMR-Gal4/UAS-foxO/UAS-lacZ (A) and 
GMR-Gal4/UAS-foxO/UAS-mnb-RNAi (B) Expression of mnb-RNAi did not alter 
ommatidia number (C), bristle number (D) or ommatidia area (E). Error bars 
represent standard error of mean and NS indicates Not Significant. 
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Expression of mnb-RNAi directed by ddc-Gal4 does not alter life span or climbing 
ability in D .melanogaster raised at 25º C. 
 
The ddc-Gal4 transgene was used to direct the expression of dsRNA for mnb-  
RNA interference in dopaminergic neurons and ddc-gal4/UAS-lacZ was used as a 
control. N-value of 200 males of critical class was selected and the survival curves 
shown in Figure 13A suggested that both genotypes have median life span of 42 days 
and both genotypes of ddc-gal4/UAS-lacZ and ddc-Gal4/UAS-mnb-RNAi live equally 
well up to close to day 70. Mantel-Cox statistical test did not reveal any significant 
difference in their survival pattern. Figure 13B displays non-linear regression curves 
of climbing over time for two genotypes of ddc-Gal4/UAS-lacZ and ddc-Gal4/UAS-
mnb-RNAi. Results of statistical analysis on climbing over time in two genotypes of 
ddc-Gal4/UAS-lacZ and ddc-Gal4/UAS-mnb-RNAi did not reveal any significant early 
loss of climbing ability. 70 flies of critical class were selected initially until the 
minimum of five flies to assess their climbing ability and the result of comparison 
shows that slopes of the curves overlap indicating that any seen differences is 
probably a result of chance. 
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Figure 13. The expression of mnb-RNAi directed by ddc-Gal4 did not alter life 
span or climbing ability in D. melanogaster raised at 25 º C. A Longevity assay 
results do not reveal any significant difference in life span in genotypes of ddc-
Gal4/UAS-lacZ and ddc-Gal4/UAS-mnb-RNAi. Longevity test was carried out on 200 
flies of critical class and the statistical analysis, Mantel-Cox test, was used to detect 
significant difference in their survival pattern. Both genotypes presented a median life 
span of 42 days and grew equally well on standard media up to day 70. B mnb-RNAi 
directed by ddc-Gal4 did not change climbing ability over time compared to ddc-
Gal4/UAS-lacZ.  
A 
B 
ddc-Gal4/UAS-lacZ 
ddc-Gal4/UAS-mnb-RNAi 
d c-Gal4/UAS-mnb-RNAi 
ddc-Gal4/UAS-lacZ 
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Expression of mnb-RNAi directed by TH-Gal4 does not alter survival but significantly 
diminishes climbing ability.  
 
mnb-RNAi expressed  by TH-Gal4 transgene revealed significant decrease in  
climbing ability but did not alter survival. Figure 14A suggests that there was no 
significant difference in life span of the two genotypes. TH-Gal4/UAS-lacZ and TH-
Gal4/UAS-mnb-RNAi both showed a median life span of 58 days and they remained 
alive until day 78. Their climbing ability over time, however, illustrated in Figure 14B 
demonstrates a significant loss when mnb-RNAi is expressed in dopaminergic neurons 
directed by TH-Gal4. Pairwise, day to day comparison of climbing ability over time 
for two genotypes of TH-Gal4/UAS-lacZ and TH-Gal4/UAS-mnb-RNAi flies revealed 
that the decline in climbing ability in day 26, 40 and 47 is significant. 200 flies of 
critical class were analysed for longevity assay and 70 flies initially were selected for  
the locomotor assay and climbing over time until minimum of 5 flies were left alive. 
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Figure 14. The expression of mnb-RNAi in dopaminergic neurons using TH-Gal4 
transgene does not alter life span but decreases climbing ability significantly in 
D. melanogaster raised at 25 º C. life span was not reduced or increased when mnb-
RNAi is expressed under the control of TH-Gal4 transgene, N-value=200 (A). 
Climbing ability was reduced considerably at days 26, 40 and 47 when mnb-RNAi was 
induced in dopaminergic neurons using TH-Gal4 transgene, N-value =70 (initially) 
and 5 (minimum) (B) Error bars represent standard error of mean and asterisk 
indicates significant difference. 
A 
B 
* 
* 
* 
* 
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DISCUSSION 
 
As foxO1 has been recently implicated as playing a role in Parkinson Disease  
(Dumitriu et al., 2012), I investigated the potential of modelling PD in Drosophila by 
altering foxO activity. This study is in support of evidence from human whole genome 
microarray implying a role of foxO1 gene in PD prevalence. Since the previous study 
showed that foxO1 genes and the genes under its regulation increase significantly in 
PD patients, I decided that if we can elevate  Drosophila foxO in dopaminergic 
neurons and this mimics PD-like phenotype, I can model this aspect of PD (with 
increased foxO) and provide it for further studies. So, my initial hypothesis was that 
by elevating foxO in dopaminergic neurons I should result in a similar phenotype as in 
other PD models such as decreased climbing abilities. Since directly elevating foxO in 
dopaminergic neurons is lethal in Drosophila (Staveley, unpublished), I decided to 
attempt to increase foxO in dopaminergic neurons only to a modest extent and 
indirectly to avoid detrimental effects of its direct overexpression. To do so, I took 
advantage of pre-existing conditionally expressed RNAi transgenic lines and I took an 
approach to indirectly increase foxO by inhibiting its inhibitors. There are a number of 
gene products have been demonstrated to alter the activity of foxO (reviewed in 
Arden, 2006).  
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Although initially mnb and akt were considered as potential post-translational  
modifiers of foxO, flies expressing the akt-RNAi transgene proved to be not vigorous 
enough to carry out experiments upon (data not shown). FKHR (foxO1) is 
phosphorylated by human dYRK1A on Serine 329 (Woods et al., 2001), so I decided 
to evaluate the effects of foxO modulation on longevity, locomotion ability and eye 
development. I utilized foxO-RNAi to directly decrease foxO expression and mnb-
RNAi for slight, indirect elevation in foxO activity. Initially, I tested the candidate 
lines of UAS-lacZ and UAS-GFP-RNAi to find out which one functioned as a more 
suitable control for the experiments.  
Results suggest that expression of GFP-RNAi directed by TH-Gal4 in  
dopaminergic neurons results in a significant decrease in life span (Figure 4A). This 
result is found consistent with a previous study conducted showing that applying 
GFP-RNAi can have detrimental effects (Alic et al., 2012). This reduced life span 
might occur due to targeting of a similar sequence as GFP mRNA thus making a 
complementary structure with GPF-RNAi which eventually leads to some adverse 
effects on life span.  Although locomotion does not seem to be altered when GFP-
RNAi is expressed in dopaminergic neurons directed by ddc-Gal4 and TH-Gal4 
(Figures 3B and 4B) and longevity is not influenced when GFP-RNAi is expressed 
directed by ddc-Gal4 (Figure 3A), it is concluded that UAS-GFP-RNAi may not 
function as a benign control as hypothesized initially. So, I decided to conduct the rest 
of my experiments with UAS-lacZ 
4-1-2
 as the control line. 
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The results of foxO-RNAi expression in the eye and in dopaminergic neurons  
suggest that a slight decrease in foxO in the eye directed by GMR-Gal4 transgene does 
not have any significant effect on eye development as demonstrated by unaffected 
ommatidia number, bristle number and ommatidia area (Figure 5). The result here 
suggests that Drosophila eye development is not critically sensitive to the alteration of 
endogenous foxO caused by foxO-RNAi and taking out slight amounts of foxO in the 
eye does not alter its development significantly. Overexpression of foxO in the eye 
results in a phenotype characterized by misformed eye shape with reduced number of 
ommatidia and bristles (Figure 6A). The foxO-RNAi expression directed by GMR-
GAL4/UAS-foxO can suppress the phenotype shown by increased number of 
ommatidia and bristle (Figures 6C and 6D). The results suggest that directed 
expression of foxO-RNAi can supress the effect of exogenous foxO and partially 
reverse or rescue the phenotype. foxO-RNAi expression in dopaminergic neurons gives 
two distinct results: 1) foxO-RNAi directed by ddc-Gal4 does not alter life span or 
climbing ability compared to ddc-Gal4/UAS-lacZ (Figure 7); 2) foxO-RNAi expression 
directed by TH-Gal4 decreases life span significantly but does not alter locomotion 
over time when directed by ddc-Gal4 transgene (Figure 7). Reduced life span in foxO-
RNAi flies in their dopaminergic neurons (using TH-Gal4 as driver line and not with 
ddc-Gal4) compared to UAS-lacZ flies suggested a protective role for foxO against 
cell death in dopaminergic neurons (Li et al., 2012).  
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Directed expression of mnb-RNAi in the eye by GMR-Gal4 transgene does not  
alter eye development significantly as shown by unaffected ommatidia number; 
ommatidia area and bristle number (Figure 9) and the inhibition of mnb using mnb-
RNAi directed by GMR-Gal4/UAS-foxO does not display any significant change in the 
eye either (Figure 10). From the result obtained, it can be deduced that inhibition of 
mnb in the eye both in the presence of exogenous foxO or in its absence is not 
significant to eye development. This finding is consistent with the result that mnb 
mutants present fairly normal eyes and that decrease in mnb levels does not alter eye 
development significantly (Tejedor et al., 1995). Expression of mnb-RNAi in 
dopaminergic neurons exhibit two different results: 1) directed by ddc-Gal4, mnb-
RNAi expression does not alter life span or longevity compared to that of ddc-
Gal4/UAS-lacZ (Figure 11); 2) expression of mnb-RNAi in dopaminergic neurons 
using TH-Gal4 transgene, altered climbing ability over time but did not alter life span 
(Figure 12).The difference in expression array presented by the two transgenes may 
account for the observed difference in results; the ddc-Gal4 transgene direct the 
expression of Gal4 and hence the gene under the control of UAS element in a slightly 
different and wider area than that of the TH-Gal4 transgene. In fact, dopa 
decarboxylase enzyme is synthesized in the 150 dopamine and serotonin neurons and 
in a subset of glial cells and in the most hypodermal cells whereas TH is expressed in 
dopamine synthesizing cells (Alic et al., 2012). Another possible explanation for the 
observed difference is that the expression of protein Gal4 may not be as robust in ddc-
Gal4 as it is with TH-Gal4 transgene.  
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A significant decrease in climbing ability at days 26, 40 and 47 can be due to  
slight elevation of foxO caused by mnb-RNAi in dopaminergic neurons. If so, it is 
consistent with the results from a genome wide study (Dumitriu et al., 2012) 
indicating the role of foxO increase in Parkinson Disease. Nevertheless, as there is a 
growing body of evidence on the regulatory effects of dyrk1A/mnb on foxO in 
different cellular processes including metabolism and cell growth (including Hong et 
al., 2012) and with the experimental set-ups in my project, I can deduce that slight 
inhibition of mnb can mimic some aspects of PD in Drosophila. 
The foxO transcription factor promotes the expression of different genes  
including MnSOD, Cyclin G2, NPY and Bim1 thus playing role in different cellular 
processes (further experiments can be done to identify which downstream genes are 
altered in case of up/down regulation of foxO). While many studies  including 
Hossain et al., 2013 study) suggest that foxO protects against cell death particularly in 
food reduced conditions and other stress-causing conditions by acting as an innate 
immunity foster element (Wang et al., 2014), some other papers (including Fu and 
Tindall, 2008) point to the flip side and indicate that foxO plays a role in inducing 
apoptosis exhibiting as a tumour suppressor in a variety of cancers (by inducing the 
expression of death receptor ligands such as Fas ligand Bcl-2 family members). So it 
seems that foxO can play roles in several physiological processes at different 
developmental stages and environmental conditions.  
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The apparent complexity in verifying results may call for repeating similar 
experiments to verify these results or trade them for new, more precise findings which 
can be one way of looking at future studies. Other ways of progressing with studies of 
this nature will be the same studies with more accurate assessment techniques for 
example better performing climbing system like the one described in Podratz et al., 
2013 as the currently used manual system is laborious, time-consuming and subject to 
human error. One other aspect of continuing and improving this study is to employ 
new techniques such as immunohistochemistry to evaluate the presence of dopamine 
in Parkinson Disease models. In addition, for assuring the actual expression of a 
certain construct in prepared fly lines, one can benefit from the techniques that 
evaluate the expression or even quantifies them such as qPCR. Other ways of 
evaluating the role of certain genes in cell death behaviour may involve gene knock-
downs in Drosophila embryo and evaluating caused alterations in developing flies 
with fluorescence detection or other macroscopic measurements such as size 
measurements or morphological assessments. Plus, foxO activity or modulation of 
transcriptional targets could also be assessed. To verify actual alteration in levels of 
mnb or foxO, immunohistochemical staining in brain tissue or the eye (depending on 
the experiment rationale) can be performed. 
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Conclusion: 
 
Supported by the results, as the initial prediction was, expressing mnb-RNAi in  
dopaminergic neurons using the TH-Gal4 transgene seems to partially mimic/model 
some aspects of Parkinson Disease but does not do so with ddc-Gal4 tested by 
climbing test (as described by Todd and Staveley, 2004).  
 
Results do not support the hypothesis that GFP-RNAi transgene can function  
as a suitable control. Expression of GFP-RNAi directed by TH-Gal4 leads into 
significant reduced life span therefore GFP-RNAi may not be operating as a benign 
control. 
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